TB CAB Access Considerations Statement Regarding Johnson & Johnson Announcement of Bedaquiline Price Reduction

Bedaquiline is a public good, and must be treated as such. Johnson & Johnson once again refused to meet evidence-based demands to price bedaquiline at $1/day.

120,707 people signed petitions urging the corporation to drop the price.

Stop TB Partnership and Johnson & Johnson, with support from USAID and the Global Fund, announce price reduction for bedaquiline for treatment of drug-resistant TB in low- and middle-income countries.

WHO releases updated guidelines for TB diagnosis, recommending rapid molecular tests as initial tests for TB detection.

WHO releases updated guidelines for the treatment of drug-resistant TB.

Organizations are invited to sign on to a Call to Action on HIV, TB and COVID-19 developed by Frontline AIDS, ARASA, Global Coalition of TB Activists and TBpeople, alongside community organizations.

The 73rd World Health Assembly adopts a resolution to bring the world together to fight the COVID-19 pandemic.

Community-led health service delivery has become even more critical in the context of COVID-19, as the needs of marginalized community members and the burden on the health sector are increasing, making it vital that continued provision of HIV, TB and other health services is secured.

More investment and greater collective efforts needed now if global TB preventive treatment (TPT) targets are to be met.